- Advertisement -
- Advertisement -

Rhenman & Partners Boosts Biopharma Expertise

- Advertisement -

Stockholm (HedgeNordic) – Rhenman & Partners is expanding its five-person investment team with the hiring of Amennai Beyeen as a biopharma analyst. He joins from global healthcare company Novartis.

“We are very happy to welcome Amennai to Rhenman & Partners,” says Henrik Rhenman, co-founder and CIO at Rhenman & Partners. “Amennai’s strong background and competence from the world of research, and his experience of pharmaceutical companies where he has been able to closely follow processes from idea to finished product make him a very good addition to our investment team.”

“We are very happy to welcome Amennai to Rhenman & Partners.”

Amennai Beyeen has worked for about 12 years at Novartis, focusing on the development and launch of new drugs. He also holds a doctorate in neuroimmunology from Karolinska Institutet in Stockholm. Beyeen will join the five-person investment team running the healthcare-focused equity hedge fund Rhenman Healthcare Equity L/S. He will have a particular focus on biopharma companies and the development of new drugs and treatments.

“It is very exciting to start at Rhenman & Partners,” Amennai Beyeen comments on joining the Swedish healthcare-focused asset manager. “I am extremely impressed by the team’s deep knowledge of the healthcare sector as well as the fund’s versatile investment process, which is reflected in its strong results over the years,” he continues. “I look forward to joining this competent team and contributing with my experience from the life science sector.”

Rhenman & Partners Asset Management has been running its long-biased equity hedge fund with an exclusive focus on healthcare since mid-2009, delivering an annualized return of 17.3 percent through November 2022. The fund’s main share class (IC1 EUR) edged down 1.6 percent in the first 11 months of this year. Rhenman Healthcare Equity L/S oversees €923 million in assets under management.

Subscribe to HedgeBrev, HedgeNordic’s weekly newsletter, and never miss the latest news!

Our newsletter is sent once a week, every Friday.

Eugeniu Guzun
Eugeniu Guzun
Eugeniu Guzun serves as a data analyst responsible for maintaining and gatekeeping the Nordic Hedge Index, and as a journalist covering the Nordic hedge fund industry for HedgeNordic. Eugeniu completed his Master’s degree at the Stockholm School of Economics in 2018. Write to Eugeniu Guzun at eugene@hedgenordic.com

Latest Articles

Rhenman Embracing Change Amid an Ever-Changing Healthcare Sector

Stockholm (HedgeNordic) – The largest equity hedge fund in the Nordics with assets under management just shy of $1 billion, the Rhenman healthcare fund,...

Inside Ilmarinen’s Approach to Hedge Fund Allocation

Stockholm (HedgeNordic) – Ilmarinen, in a tight race with Varma as Finland’s largest earnings-related pension insurance company, has emerged as a noteworthy investor in...

Nordic Hedge Fund Industry Report 2024

Stockholm (HedgeNordic) – HedgeNordic’s Nordic Hedge Fund Industry Report kicks off with an analysis of the industry’s performance across different asset size ranges. This...

BlueOrchard’s Climate Insurance PE Fund Edges Toward $100M

Stockholm (HedgeNordic) – BlueOrchard’s private equity fund dedicated to climate insurance has secured commitments of close to $30 million from two new investors, British...

Smooth Sailing in Rough Seas

Stockholm (HedgeNordic) – Gersemi Shipping Fund has emerged as a notable recent addition to the Nordic hedge fund industry. However, the founder and manager...

Absolute Returns in Impact-Screened High-Yield Market

Stockholm (HedgeNordic) – While many high-yield bond investors prioritize avoiding defaults, there is one team in the Nordics that does not shy away from...

Allocator Interviews

Latest Articles

In-Depth: Emerging Markets

Voices

Request for Proposal

- Advertisement -